# 2025年10月29日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 齿状核-红核-苍白球-路易体萎缩中的癫痫：一项系统评价和荟萃分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41147955](https://pubmed.ncbi.nlm.nih.gov/41147955)
**期刊：** Epilepsia
**PMID：** 41147955
**DOI：** 10.1111/epi.18700

### 第一部分 原文与翻译

**英文原标题：** Epilepsy in dentatorubral-pallidoluysian atrophy: A systematic review and meta-analysis.

**英文摘要原文：**
OBJECTIVE: Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare autosomal dominant neurodegenerative disease caused by a CAG repeat expansion in the ATN1 gene. The juvenile onset type often presents with epilepsy, including progressive myoclonic epilepsy (PME). However, evidence on epilepsy in DRPLA remains limited. This systematic review and meta-analysis aimed to summarize clinical characteristics of DRPLA-related epilepsy.

METHODS: We systematically searched MEDLINE (PubMed), CENTRAL, Embase, Ichushi, and ClinicalTrials.gov for studies on DRPLA-related epilepsy, following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The review protocol was registered with the Open Science Framework. Any study design reporting at least one case of DRPLA-related epilepsy was eligible, including case reports, case series, cohort studies, and clinical trials. Eligible studies underwent screening and full-text assessment, followed by inclusion in descriptive and meta-analytic syntheses. Meta-analyses included only studies reporting ≥5 DRPLA patients.

RESULTS: A total of 181 studies encompassing 1191 patients met the eligibility criteria. DRPLA patients with epilepsy had a younger onset age (16.9 [95% confidence interval (CI) = 13.76-20.76] vs. 45.5 years [95% CI = 42.77-48.47]) and more CAG repeats (66.7 [95% CI = 63.63-69.84] vs. 59.2 [95% CI = 55.67-62.92]) than those without epilepsy. DRPLA patients with epilepsy showed a higher likelihood of paternal versus maternal inheritance (odds ratio = 2.47 [95% CI = .97-6.27]). Focal seizures were frequently observed (40.0%-76.5%) alongside myoclonic and generalized tonic-clonic seizures. Electroencephalographic findings included slow bursts (38.0%), photoparoxysmal responses (36.6%), and interictal epileptiform discharges (77.5%). Giant somatosensory-evoked potentials, typically seen in PME, were observed in only two patients and absent in 27. Among antiseizure medications, perampanel and levetiracetam were more frequently reported as effective than sodium channel blockers.

SIGNIFICANCE: This review synthesizes fragmented evidence on DRPLA-related epilepsy and highlights key clinical and electrophysiological patterns. Despite limitations from small-scale studies, these findings support more informed clinical care and underscore the need for larger cohort studies.

**中文摘要译文：**
目的：齿状核-红核-苍白球-路易体萎缩（DRPLA）是一种罕见的常染色体显性遗传神经退行性疾病，由ATN1基因CAG重复扩增引起。青少年发病型常表现为癫痫，包括进行性肌阵挛性癫痫（PME）。然而，关于DRPLA中癫痫的证据仍然有限。本系统评价和荟萃分析旨在总结DRPLA相关癫痫的临床特征。

方法：我们按照PRISMA（系统评价和荟萃分析优先报告项目）指南，系统检索了MEDLINE（PubMed）、CENTRAL、Embase、Ichushi和ClinicalTrials.gov中关于DRPLA相关癫痫的研究。评价方案已在开放科学框架中注册。任何报告至少一例DRPLA相关癫痫的研究设计均符合条件，包括病例报告、病例系列、队列研究和临床试验。符合条件的研究经过筛选和全文评估，随后纳入描述性和荟萃分析综合。荟萃分析仅包括报告≥5例DRPLA患者的研究。

结果：共有181项研究涵盖1191例患者符合入选标准。与无癫痫的DRPLA患者相比，有癫痫的DRPLA患者发病年龄更小（16.9岁[95%置信区间(CI)=13.76-20.76] vs. 45.5岁[95% CI=42.77-48.47]），CAG重复次数更多（66.7[95% CI=63.63-69.84] vs. 59.2[95% CI=55.67-62.92]）。有癫痫的DRPLA患者显示出父系遗传相对于母系遗传的更高可能性（比值比=2.47[95% CI=0.97-6.27]）。局灶性发作（40.0%-76.5%）与肌阵挛性和全面性强直-阵挛发作一起频繁观察到。脑电图发现包括慢波爆发（38.0%）、光阵发性反应（36.6%）和发作间期癫痫样放电（77.5%）。通常在PME中观察到的巨大体感诱发电位仅在两名患者中观察到，在27名患者中不存在。在抗癫痫药物中，吡仑帕奈和左乙拉西坦比钠通道阻滞剂更常被报告为有效。

意义：本评价综合了关于DRPLA相关癫痫的零散证据，并突出了关键的临床和电生理模式。尽管存在小规模研究的局限性，这些发现支持更明智的临床护理，并强调了进行更大规模队列研究的必要性。

### 第二部分 AI 大师评价

本研究通过系统评价和荟萃分析，首次全面总结了DRPLA相关癫痫的临床特征，填补了该罕见病领域的重要知识空白。研究采用严格的PRISMA指南，整合了181项研究中的1191例患者数据，揭示了癫痫型DRPLA患者具有更早发病年龄、更多CAG重复次数和父系遗传倾向等关键特征。创新性地发现了吡仑帕奈和左乙拉西坦在DRPLA相关癫痫治疗中的潜在优势，为临床用药提供了重要参考。尽管受限于小样本研究的局限性，但本研究为这一罕见疾病的精准诊疗奠定了基础，具有重要的临床指导价值，并强调了未来需要更大规模队列研究来验证这些发现。

---

## 2. Olig2特异性功能缺失Slc35a2导致髓鞘形成不足和自发性癫痫发作

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41144763](https://pubmed.ncbi.nlm.nih.gov/41144763)
**期刊：** Epilepsia
**PMID：** 41144763
**DOI：** 10.1111/epi.18697

### 第一部分 原文与翻译

**英文原标题：** Olig2-specific loss-of-function Slc35a2 results in hypomyelination and spontaneous seizures.

**英文摘要原文：**
OBJECTIVE: Malformations of cortical development represent major causes of drug-resistant epilepsy, with mild malformation of cortical development with oligodendroglial hyperplasia and epilepsy recognized as a distinct pathological entity. Pathogenic X-linked SLC35A2, encoding the uridine diphosphate-galactose transporter, has been implicated in this condition. In this study, we investigated the behavioral, electrophysiological, and cellular/molecular phenotypes associated with loss-of-function Slc35a2 mutations in oligodendrocytes.

METHODS: A conditional knockout (cKO) mouse model was generated using an Olig2-specific promoter. Behavioral assessments included neurological scoring, open field, locomotor habituation, and pentylenetetrazole-induced seizure testing in 95 mice (31 female controls, 22 female cKO, 26 male controls, 16 male cKO), aged 4-18 weeks. Continuous electroencephalographic (EEG) studies were performed in eight control and eight cKO mice implanted with cortical electrodes. Histopathological analyses and immunohistochemistry were performed at postnatal days 15, 21, and 60.

RESULTS: Loss-of-function Slc35a2 mice exhibited significantly reduced body weight, progressive motor dysfunction, and reduced survival compared to controls. Males demonstrated more severe motor dysfunction compared to females due to the X-linked nature of Slc35a2. Video-EEG monitoring captured spontaneous electroclinical seizures in cKO mice, accompanied by frequent interictal spiking, despite preserved neuronal integrity. Histological and immunohistochemical evaluation revealed extensive subcortical hypomyelination, reactive gliosis, and significant reduction of Olig2-positive oligodendrocytes in the corpus callosum.

SIGNIFICANCE: Our results demonstrate that loss of SLC35A2 function in oligodendrocytes is sufficient to reproduce pathological and clinical features observed in human mild malformation of cortical development with oligodendroglial hyperplasia and epilepsy. Spontaneous seizures in the absence of direct neuronal genetic abnormalities highlight a central role for oligodendrocyte dysfunction and hypomyelination in epileptogenesis. These findings challenge the neuron-centric view of epilepsy and suggest that targeting glial dysfunction may offer novel therapeutic opportunities. Further studies are warranted to delineate cellular interactions driving epileptogenesis and to explore glia-centered treatment strategies for drug-resistant epilepsies.

**中文摘要译文：**
目的：皮质发育畸形是耐药性癫痫的主要病因，其中伴有少突胶质细胞增生和癫痫的轻度皮质发育畸形被确认为一个独特的病理实体。致病性X连锁SLC35A2基因编码尿苷二磷酸-半乳糖转运蛋白，已被证实与该疾病相关。在本研究中，我们研究了少突胶质细胞中Slc35a2功能缺失突变相关的行为、电生理和细胞/分子表型。

方法：使用Olig2特异性启动子构建了条件性敲除（cKO）小鼠模型。行为评估包括神经学评分、旷场实验、运动习惯化和戊四唑诱导的癫痫发作测试，涉及95只小鼠（31只雌性对照、22只雌性cKO、26只雄性对照、16只雄性cKO），年龄为4-18周。在8只对照和8只cKO小鼠中进行了连续脑电图（EEG）研究，这些小鼠植入了皮质电极。在出生后第15、21和60天进行了组织病理学分析和免疫组织化学检测。

结果：与对照组相比，Slc35a2功能缺失小鼠表现出显著降低的体重、进行性运动功能障碍和生存率降低。由于Slc35a2的X连锁性质，雄性小鼠表现出比雌性更严重的运动功能障碍。视频-脑电图监测在cKO小鼠中捕捉到自发性电临床癫痫发作，伴有频繁的发作间期棘波，尽管神经元完整性得以保持。组织学和免疫组织化学评估显示广泛的皮质下髓鞘形成不足、反应性胶质增生以及胼胝体中Olig2阳性少突胶质细胞的显著减少。

意义：我们的结果表明，少突胶质细胞中SLC35A2功能的丧失足以重现人类伴有少突胶质细胞增生和癫痫的轻度皮质发育畸形中观察到的病理和临床特征。在没有直接神经元遗传异常的情况下出现自发性癫痫发作，突显了少突胶质细胞功能障碍和髓鞘形成不足在癫痫发生中的核心作用。这些发现挑战了以神经元为中心的癫痫观点，并表明靶向胶质细胞功能障碍可能提供新的治疗机会。需要进一步研究来阐明驱动癫痫发生的细胞相互作用，并探索以胶质细胞为中心的治疗策略，用于耐药性癫痫。

### 第二部分 AI 大师评价

本研究通过构建Olig2特异性Slc35a2条件敲除小鼠模型，深入探讨了少突胶质细胞功能障碍在癫痫发生中的关键作用。研究采用多学科方法，包括行为学评估、连续脑电图监测和详细的组织病理学分析，系统揭示了Slc35a2功能缺失导致的髓鞘形成不足、运动功能障碍和自发性癫痫发作。该研究的创新性在于挑战了传统的神经元中心论，首次证实少突胶质细胞特异性基因缺陷足以诱发癫痫，为理解癫痫发病机制提供了全新视角。这一发现具有重要的临床意义，为开发针对胶质细胞功能障碍的新型抗癫痫治疗策略开辟了道路，尤其对难治性癫痫患者具有潜在治疗价值。然而，研究仍需进一步阐明少突胶质细胞与神经元之间的相互作用机制，以及性别差异对疾病表型的影响。

---

## 3. 新生SRCAP变异导致发育性和癫痫性脑病及其表型谱

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41144712](https://pubmed.ncbi.nlm.nih.gov/41144712)
**期刊：** Epilepsia
**PMID：** 41144712
**DOI：** 10.1111/epi.18695

### 第一部分 原文与翻译

**英文原标题：** De novo SRCAP variants cause developmental and epileptic encephalopathy and the phenotypic spectrum.

**英文摘要原文：**
OBJECTIVE: The SRCAP gene encodes a core catalytic subunit of adenosine triphosphate-dependent chromatin remodeling complexes that play an essential role in chromatin regulation and neurodevelopment. Our recent study showed that the EP400 gene, the paralog of SRCAP, is associated with neurodevelopmental disorders and epilepsy. This study aims to explore the relationship between SRCAP and developmental and epileptic encephalopathy (DEE) and the phenotypic spectrum of SRCAP variants.

METHODS: Trio-based whole-exome sequencing was performed on patients with DEE from the China Epilepsy Gene 1.0 Project Cohort. Additional cases were screened from other subcohorts. The gene-disease association was validated by minor allele frequency (MAF), damaging effect of variants, genotype-phenotype correlation, and studies on spatial-temporal and single-cell expression.

RESULTS: De novo heterozygous SRCAP variants were identified in five patients with DEE. These variants were truncations or missense variants of severe damage characterized by significant changes in hydrophobicity and protein stability/hydrogen bonding. Additional SRCAP variants were identified in six patients with focal epilepsy (FE), including refractory FE. These variants were characterized by biallelic variants of mild damage, such as in-frame indel or missense with fewer changes in hydrophobicity and protein stability/hydrogen bonding, which were correlated with the severity of phenotype and outcomes. The epilepsy-associated variants presented statistically lower MAF than benign variants, with the lowest MAF in DEE-associated variants. Compared to EP400, SRCAP presented higher expression in the brain throughout the lifespan. In the late developmental brain, EP400 is predominantly expressed in excitatory neurons, in contrast to the higher proportion of SRCAP expression in inhibitory neurons, explaining the association of SRCAP variants with DEE and refractory FE.

SIGNIFICANCE: SRCAP is associated with epilepsy and DEE. The phenotypic spectrum ranges from DEE/multisystem developmental disorders to FE of varied severity, depending on the damage of variants. The development-dependent expression pattern of neuron specificity explains the underlying mechanism of epilepsy outcomes.

**中文摘要译文：**
目的：SRCAP基因编码ATP依赖性染色质重塑复合物的核心催化亚基，在染色质调控和神经发育中发挥重要作用。我们最近的研究表明，SRCAP的旁系同源基因EP400与神经发育障碍和癫痫相关。本研究旨在探索SRCAP与发育性和癫痫性脑病（DEE）的关系以及SRCAP变异的表型谱。

方法：对中国癫痫基因1.0项目队列中的DEE患者进行基于三人的全外显子组测序。从其他亚队列中筛选了额外病例。通过次要等位基因频率（MAF）、变异的破坏效应、基因型-表型相关性以及时空和单细胞表达研究验证了基因-疾病关联。

结果：在五名DEE患者中鉴定出新生杂合SRCAP变异。这些变异是截断或错义变异，具有严重破坏性，其特征是疏水性和蛋白质稳定性/氢键发生显著变化。在六名局灶性癫痫（FE）患者（包括难治性FE）中鉴定出额外的SRCAP变异。这些变异以轻度破坏的双等位基因变异为特征，例如框内插入缺失或疏水性和蛋白质稳定性/氢键变化较少的错义变异，这些变异与表型和结局的严重程度相关。癫痫相关变异的MAF在统计学上低于良性变异，其中DEE相关变异的MAF最低。与EP400相比，SRCAP在整个生命周期中在大脑中呈现更高的表达。在晚期发育大脑中，EP400主要在兴奋性神经元中表达，而SRCAP在抑制性神经元中的表达比例更高，这解释了SRCAP变异与DEE和难治性FE的关联。

意义：SRCAP与癫痫和DEE相关。表型谱范围从DEE/多系统发育障碍到不同严重程度的FE，取决于变异的破坏程度。神经元特异性的发育依赖性表达模式解释了癫痫结局的潜在机制。

### 第二部分 AI 大师评价

本研究首次系统阐明了SRCAP基因变异与癫痫谱系疾病的关联机制，具有重要的创新价值。研究采用三人全外显子测序结合多组学验证的方法，发现SRCAP新生变异导致严重发育性癫痫脑病，而双等位基因轻度变异则与局灶性癫痫相关，建立了清晰的基因型-表型对应关系。关键发现揭示了SRCAP在抑制性神经元中的特异性表达模式，为理解癫痫发病机制提供了新的分子基础。该研究不仅拓展了癫痫遗传学病因谱系，更为精准诊断和靶向治疗提供了理论依据，但样本量相对有限，需要在更大队列中进一步验证。

---

## 4. 一项评估辅助性西诺巴胺在亚洲局灶性癫痫患者中疗效和安全性的随机、双盲、安慰剂对照、多中心研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41144696](https://pubmed.ncbi.nlm.nih.gov/41144696)
**期刊：** Epilepsia
**PMID：** 41144696
**DOI：** 10.1111/epi.18698

### 第一部分 原文与翻译

**英文原标题：** A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures.

**英文摘要原文：**
OBJECTIVES: This randomized, double-blind, placebo-controlled study (NCT04557085), conducted in China, Japan, and the Republic of Korea, evaluated the efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures.

METHODS: Adults 18-70 years of age with ≥8 seizures (focal aware motor, focal impaired awareness, or focal to bilateral tonic-clonic) during an 8-week baseline, despite treatment with 1-3 antiseizure medications (ASMs), were randomized 1:1:1:1 to placebo or cenobamate 100, 200, or 400 mg/day. The study included an 18-week titration phase and a 6-week maintenance phase. The primary efficacy analysis was a hierarchical step-down comparison of the percent change from baseline in 28-day seizure frequency vs placebo during the maintenance phase for cenobamate 200, then 400, and then 100 mg/day.

RESULTS: Among 519 patients randomized, 446 received ≥1 dose of study drug and had ≥1 efficacy measure during the maintenance phase (placebo, n = 117; 100 mg/day, n = 113; 200 mg/day, n = 113; and 400 mg/day, n = 103). Median percent change in seizure frequency during the maintenance phase was -25.9% for placebo vs -42.6%, -78.3%, and -100% for cenobamate 100, 200, and 400 mg/day, respectively (all p's < .001). During the 12-week period encompassing the last 6 weeks of titration and the 6-week maintenance phase (secondary outcome), the median percent change in seizure frequency was -20.1% for placebo vs -42.6%, -77.1%, and -89.2% for cenobamate 100, 200, and 400 mg/day, respectively. Seizure-free rates during the maintenance phase were 2.6% of patients for placebo vs 12.4%, 30.1%, and 52.4% for cenobamate 100, 200, and 400 mg/day, respectively, and during the 12-week period were 0.8% for placebo vs 8.5%, 19.7%, and 30.6% for the cenobamate groups. The most common treatment-emergent adverse events in cenobamate patients (≥20%) were dose-related dizziness and somnolence.

SIGNIFICANCE: Cenobamate 100, 200, and 400 mg/day reduced focal seizures in Asian patients in a dose-related fashion and was generally well tolerated.

**中文摘要译文：**
目的：这项在中国、日本和韩国进行的随机、双盲、安慰剂对照研究（NCT04557085）评估了辅助性西诺巴胺在未受控制的局灶性癫痫患者中的疗效和安全性。

方法：年龄18-70岁的成人，在8周基线期内尽管接受1-3种抗癫痫药物治疗，仍有≥8次癫痫发作（局灶性意识保留运动性发作、局灶性意识障碍性发作或局灶性进展为双侧强直-阵挛性发作），按1:1:1:1随机分配至安慰剂组或西诺巴胺100、200或400毫克/天组。研究包括18周的剂量滴定阶段和6周的维持阶段。主要疗效分析采用分层逐步比较法，比较西诺巴胺200毫克/天、400毫克/天和100毫克/天在维持阶段28天癫痫发作频率相对于基线的百分比变化与安慰剂的差异。

结果：在随机分配的519名患者中，446名在维持阶段接受了≥1剂研究药物并具有≥1项疗效测量指标（安慰剂组n=117；100毫克/天组n=113；200毫克/天组n=113；400毫克/天组n=103）。维持阶段癫痫发作频率的中位百分比变化为：安慰剂组-25.9% vs 西诺巴胺100、200和400毫克/天组分别为-42.6%、-78.3%和-100%（所有p值<0.001）。在包含滴定阶段最后6周和6周维持阶段的12周期间（次要结局），癫痫发作频率的中位百分比变化为：安慰剂组-20.1% vs 西诺巴胺100、200和400毫克/天组分别为-42.6%、-77.1%和-89.2%。维持阶段无癫痫发作率分别为：安慰剂组2.6% vs 西诺巴胺100、200和400毫克/天组分别为12.4%、30.1%和52.4%；在12周期间分别为：安慰剂组0.8% vs 西诺巴胺组分别为8.5%、19.7%和30.6%。西诺巴胺患者中最常见的治疗相关不良事件（≥20%）为剂量相关的头晕和嗜睡。

意义：西诺巴胺100、200和400毫克/天以剂量相关的方式减少了亚洲患者的局灶性癫痫发作，并且总体耐受性良好。

### 第二部分 AI 大师评价

本研究是一项重要的多中心随机对照试验，专门针对亚洲人群评估新型抗癫痫药物西诺巴胺的疗效和安全性。研究设计严谨，采用随机双盲安慰剂对照方法，在三个亚洲国家开展，具有很好的临床代表性。关键发现显示西诺巴胺在100-400mg剂量范围内呈现明显的剂量-效应关系，特别是400mg组在维持期实现了100%的中位发作频率降低和52.4%的无发作率，疗效显著优于安慰剂。该研究的创新性在于首次在亚洲人群中系统验证了西诺巴胺的疗效，为亚洲癫痫患者提供了重要的治疗选择，但研究随访时间相对较短，长期安全性和疗效仍需进一步观察。

---

速递结束，祝您工作愉快！